The Latest Cardiac and Vascular News
SINGAPORE, Feb. 4, 2022 /PRNewswire/ — Genesis MedTech Group (Genesis or Group) has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases. The acquisition means that Genesis […]
DUBLIN–(BUSINESS WIRE)–CroíValve, a Dublin based medical device company developing a novel treatment for tricuspid regurgitation, has raised a Series A round to fund a Feasibility clinical study with its DUO Coaptation Valve system. This novel approach to treating tricuspid regurgitation combines the best of repair and replacement to provide the […]
New Research From Included Health Finds Virtual Care With a Holistic Approach Controls Blood Pressure SAN FRANCISCO–(BUSINESS WIRE)–According to a new study published in Mayo Clinic Proceedings: Innovations, Quality & Outcomes, utilizing virtual care visits to manage hypertensive patients demonstrated an improvement in blood pressure in 77 percent of patients. According […]
VANCOUVER and MINNEAPOLIS, Feb. 04, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (Neovasc or the Company) (NASDAQ, TSX: NVCN) today announced the publication of cost-effectiveness studies supporting the use of the Neovasc Reducer™ (“Reducer”). The two analyses, authored by Americo Cicchetti, Graduate School of Health Economics and Management (ALTEMS) at the Catholic University […]
PDUFA Target Action Date Set for November 30, 2022 FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has accepted and […]
SUNNYVALE, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. (Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. It is believed […]
AnaCardio exercises option to license a program in heart failure from Helsinn Lugano, Switzerland and Stockholm, Sweden, February 3, 2022 – Helsinn Group (“Helsinn”), a fully integrated, global biopharma company with a diversified pipeline of innovative oncology assets and strong track-record of commercial execution, and AnaCardio, a clinical stage biopharmaceutical company developing novel drugs to treat heart failure, are pleased to announce that AnaCardio has […]
Data will be available to researchers studying a wide range of disease states BOULDER, Colo., Feb. 02, 2022 (GLOBE NEWSWIRE) — SomaLogic (NASDAQ: SLGC), a leader in data-driven proteomics technology, today announced that the company will begin assaying samples from the Multi-Ethnic Study of Atherosclerosis (MESA) study beginning in the […]
Organization recognizes the most promising and innovative health startups in New York NEW YORK–(BUSINESS WIRE)–Cleerly, the company creating a new standard of care for heart disease, announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to New York’s healthcare ecosystem, has recognized the company on […]
Device enables donor lungs to safely travel unprecedented distance of 4,788 Miles with a total ischemic time of over 13 hours CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies announces a milestone achievement for its Paragonix LUNGguard™ System as the device safely completed a record distance for donor lung transport from Alaska to North Carolina. The longest […]
